sorafenib 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
Raf (Rapidely Accelerated Fibrosarcoma) kinase inhibitors 2459 284461-73-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • BAY 43-9006
  • BAY 545-9085
  • BAY-545-9085
  • sorafenib tosilate
  • sorafenib
  • nexavar
  • sorafenib tosylate
Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro. Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface kinases (KIT, FLT-3, RET, RET/PTC, VEGFR-1, VEGFR-2, VEGFR-3, and PDGFR-beta). Several of these kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis were observed in models of hepatocellular carcinoma, renal cell carcinoma, and differentiated thyroid carcinoma.
  • Molecular weight: 464.83
  • Formula: C21H16ClF3N4O3
  • CLOGP: 5.16
  • LIPINSKI: 1
  • HAC: 7
  • HDO: 3
  • TPSA: 92.35
  • ALOGS: -5.43
  • ROTB: 6
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.80 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 12.29 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 39 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
July 19, 2006 EMA BAYER AG
Dec. 20, 2005 FDA BAYER HLTHCARE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 1639.20 20.15 471 14654 22544 63451353
Hepatic function abnormal 225.99 20.15 129 14996 37013 63436884
Hepatic cancer 211.46 20.15 67 15058 4420 63469477
Diarrhoea 210.05 20.15 498 14627 714868 62759029
Hepatic encephalopathy 180.86 20.15 76 15049 11206 63462691
Decreased appetite 167.15 20.15 249 14876 250803 63223094
Off label use 138.75 20.15 412 14713 674050 62799847
Metastases to lung 134.22 20.15 64 15061 12686 63461211
Rash 129.14 20.15 357 14768 560514 62913383
Hypertension 118.96 20.15 227 14898 279076 63194821
Hyperkeratosis 115.05 20.15 46 15079 5972 63467925
Ascites 111.54 20.15 86 15039 40642 63433255
Skin exfoliation 98.81 20.15 82 15043 43020 63430877
Blister 98.21 20.15 137 14988 129677 63344220
Hepatocellular carcinoma 92.05 20.15 30 15095 2164 63471733
Drug ineffective 89.90 20.15 71 15054 1044694 62429203
Amylase increased 86.08 20.15 38 15087 6307 63467590
Alpha 1 foetoprotein increased 83.49 20.15 17 15108 177 63473720
Dry skin 75.74 20.15 80 15045 56807 63417090
Lipase increased 70.02 20.15 38 15087 9862 63464035
Hepatic failure 69.83 20.15 62 15063 35594 63438303
Pain of skin 69.60 20.15 40 15085 11594 63462303
Alopecia 63.12 20.15 200 14925 337336 63136561
Stomatitis 61.67 20.15 115 15010 138610 63335287
Erythema multiforme 60.93 20.15 35 15090 10134 63463763
Pneumonia adenoviral 58.25 20.15 12 15113 133 63473764
Erythema 54.92 20.15 126 14999 175625 63298272
Product use in unapproved indication 54.44 20.15 127 14998 178953 63294944
Skin toxicity 53.71 20.15 25 15100 4689 63469208
Ammonia increased 50.91 20.15 24 15101 4632 63469265
Drug hypersensitivity 50.66 20.15 7 15118 310680 63163217
Blood bilirubin increased 49.01 20.15 52 15073 37088 63436809
Rheumatoid arthritis 48.57 20.15 3 15122 253816 63220081
Adenoviral hepatitis 46.10 20.15 12 15113 389 63473508
Arthropathy 44.25 20.15 3 15122 234789 63239108
Condition aggravated 43.13 20.15 21 15104 402196 63071701
Platelet count decreased 42.79 20.15 89 15036 116033 63357864
Death 40.95 20.15 187 14938 374194 63099703
Food refusal 37.27 20.15 10 15115 365 63473532
Catabolic state 35.92 20.15 7 15118 57 63473840
Blood pressure increased 35.84 20.15 102 15023 161960 63311937
Mucosal inflammation 34.64 20.15 49 15076 46879 63427018
Protein induced by vitamin K absence or antagonist II increased 34.36 20.15 5 15120 3 63473894
Weight decreased 33.83 20.15 143 14982 276655 63197242
Pain in extremity 33.60 20.15 162 14963 331324 63142573
Swelling 33.31 20.15 12 15113 275366 63198531
Hypophosphataemia 33.18 20.15 25 15100 11401 63462496
Sinusitis 32.77 20.15 7 15118 226646 63247251
Liver carcinoma ruptured 32.34 20.15 5 15120 7 63473890
Joint swelling 32.33 20.15 19 15106 327647 63146250
Hyperammonaemia 31.32 20.15 18 15107 5214 63468683
Treatment failure 31.23 20.15 5 15120 199038 63274859
Oral pain 30.98 20.15 36 15089 28358 63445539
Abdominal pain 30.88 20.15 145 14980 293311 63180586
Weight increased 30.48 20.15 12 15113 260780 63213117
Pancreatic enzymes increased 30.27 20.15 10 15115 752 63473145
Renal cell carcinoma 29.87 20.15 15 15110 3320 63470577
Acute myeloid leukaemia recurrent 29.61 20.15 12 15113 1611 63472286
Tumour necrosis 29.57 20.15 10 15115 809 63473088
Hospitalisation 28.77 20.15 63 15062 85018 63388879
Pyrexia 27.58 20.15 199 14926 470279 63003618
Plantar erythema 27.13 20.15 7 15118 219 63473678
Liver disorder 27.00 20.15 47 15078 53640 63420257
Nasopharyngitis 26.14 20.15 14 15111 254243 63219654
Pain 26.10 20.15 90 15035 740538 62733359
Jaundice 25.31 20.15 33 15092 29218 63444679
Hypersensitivity 24.83 20.15 20 15105 292665 63181232
Discomfort 24.53 20.15 5 15120 167369 63306528
Disease progression 24.01 20.15 74 15051 122684 63351213
Palmoplantar keratoderma 23.98 20.15 11 15114 1996 63471901
Malignant neoplasm progression 23.57 20.15 57 15068 82064 63391833
Metastases to bone 23.52 20.15 27 15098 20992 63452905
Asthenia 23.47 20.15 164 14961 383440 63090457
Dysphonia 23.06 20.15 41 15084 47573 63426324
Tumour haemorrhage 22.87 20.15 10 15115 1621 63472276
Tumour thrombosis 22.38 20.15 4 15121 19 63473878
Arthralgia 22.30 20.15 66 15059 569644 62904253
Metastatic renal cell carcinoma 21.95 20.15 8 15117 806 63473091
Haematotoxicity 21.80 20.15 18 15107 9358 63464539
Hypocalcaemia 21.77 20.15 32 15093 31681 63442216
Wound 21.72 20.15 6 15119 163257 63310640
Skin lesion 21.09 20.15 31 15094 30690 63443207
Febrile neutropenia 20.97 20.15 69 15056 118380 63355517
Bone marrow failure 20.75 20.15 30 15095 29260 63444637
Adenovirus infection 20.61 20.15 12 15113 3559 63470338
Soft tissue necrosis 20.53 20.15 7 15118 580 63473317
Asthma 20.47 20.15 3 15122 127558 63346339

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 3852.14 16.32 1183 34811 15612 34905325
Hepatic cancer 832.01 16.32 315 35679 7960 34912977
Hepatic function abnormal 666.79 16.32 467 35527 43896 34877041
Hepatic encephalopathy 600.61 16.32 296 35698 14389 34906548
Diarrhoea 590.66 16.32 1258 34736 388654 34532283
Ascites 464.41 16.32 384 35610 46187 34874750
Decreased appetite 461.92 16.32 701 35293 165691 34755246
Hypertension 418.92 16.32 603 35391 135840 34785097
Metastases to lung 381.35 16.32 188 35806 9132 34911805
Hepatic failure 357.21 16.32 291 35703 34240 34886697
Alopecia 307.59 16.32 231 35763 24124 34896813
Alpha 1 foetoprotein increased 287.40 16.32 78 35916 629 34920308
Blister 273.62 16.32 210 35784 22648 34898289
Dysphonia 245.80 16.32 199 35795 23184 34897753
Rash 198.63 16.32 590 35404 222162 34698775
Amylase increased 168.65 16.32 94 35900 5874 34915063
Ammonia increased 146.25 16.32 77 35917 4292 34916645
Liver carcinoma ruptured 141.40 16.32 34 35960 157 34920780
Blood bilirubin increased 134.54 16.32 181 35813 38115 34882822
Jaundice 126.48 16.32 160 35834 31722 34889215
Hepatocellular carcinoma 119.44 16.32 82 35912 7427 34913510
Drug ineffective 113.84 16.32 185 35809 456566 34464371
Hyperkeratosis 111.28 16.32 61 35933 3688 34917249
Stomatitis 110.13 16.32 174 35820 42340 34878597
Oesophageal varices haemorrhage 109.74 16.32 57 35937 3089 34917848
Skin exfoliation 106.16 16.32 136 35858 27296 34893641
Toxicity to various agents 106.12 16.32 37 35957 200325 34720612
Lipase increased 104.99 16.32 83 35911 9333 34911604
Liver disorder 103.95 16.32 148 35846 32849 34888088
Fatigue 97.43 16.32 683 35311 369970 34550967
Metastases to bone 95.42 16.32 87 35907 11883 34909054
Skin toxicity 89.99 16.32 58 35936 4726 34916211
Metastases to lymph nodes 88.14 16.32 57 35937 4671 34916266
Acute kidney injury 87.13 16.32 112 35882 304876 34616061
Drug interaction 86.45 16.32 64 35930 225882 34695055
Tumour rupture 84.09 16.32 24 35970 237 34920700
Portal vein thrombosis 81.48 16.32 50 35944 3738 34917199
Completed suicide 81.18 16.32 5 35989 98163 34822774
Dry skin 75.47 16.32 124 35870 31163 34889774
Renal cell carcinoma 75.30 16.32 53 35941 4995 34915942
Overdose 74.21 16.32 5 35989 91054 34829883
Hypophosphataemia 70.56 16.32 71 35923 10955 34909982
Abdominal pain upper 65.88 16.32 192 35802 71298 34849639
Platelet count decreased 65.26 16.32 270 35724 119447 34801490
Metastases to adrenals 65.20 16.32 28 35966 984 34919953
Abdominal pain 64.13 16.32 335 35659 163283 34757654
COVID-19 63.96 16.32 4 35990 77546 34843391
Acute myeloid leukaemia recurrent 63.55 16.32 35 35959 2135 34918802
Erythema multiforme 63.40 16.32 60 35934 8589 34912348
Asthenia 61.89 16.32 448 35546 244803 34676134
Aspartate aminotransferase increased 61.45 16.32 181 35813 67602 34853335
Weight decreased 60.39 16.32 348 35646 175953 34744984
Blood pressure increased 59.73 16.32 213 35781 87889 34833048
Hepatorenal syndrome 59.41 16.32 36 35958 2630 34918307
Tumour thrombosis 53.56 16.32 14 35980 96 34920841
Pain in extremity 53.00 16.32 264 35730 126249 34794688
Pain of skin 51.84 16.32 46 35948 6063 34914874
Condition aggravated 51.32 16.32 74 35920 192122 34728815
Protein induced by vitamin K absence or antagonist II increased 50.48 16.32 10 35984 13 34920924
Drug hypersensitivity 49.77 16.32 11 35983 80518 34840419
Fall 49.51 16.32 83 35911 202802 34718135
Metastatic renal cell carcinoma 48.96 16.32 29 35965 2032 34918905
Pancreatic enzymes increased 48.56 16.32 20 35974 632 34920305
Metastases to spine 47.79 16.32 31 35963 2553 34918384
Coma hepatic 47.39 16.32 18 35976 457 34920480
Gait inability 47.01 16.32 80 35914 20678 34900259
Hypotension 46.77 16.32 99 35895 221550 34699387
Neutropenia 46.30 16.32 56 35938 156722 34764215
Metastases to central nervous system 45.61 16.32 49 35945 8156 34912781
Skin fissures 45.42 16.32 40 35954 5219 34915718
Pneumonia 44.67 16.32 207 35787 362420 34558517
Metastases to peritoneum 43.95 16.32 26 35968 1818 34919119
Cerebral infarction 40.25 16.32 88 35906 27367 34893570
Weight increased 38.65 16.32 24 35970 93009 34827928
Liver abscess 38.48 16.32 32 35962 3863 34917074
Tumour marker increased 38.44 16.32 17 35977 642 34920295
Hepatic lesion 37.72 16.32 31 35963 3681 34917256
Hepatic rupture 37.18 16.32 9 35985 43 34920894
Malignant neoplasm progression 36.32 16.32 183 35811 87863 34833074
Nephrotic syndrome 36.07 16.32 41 35953 7262 34913675
Off label use 35.42 16.32 617 35377 418907 34502030
Gastric ulcer 35.02 16.32 60 35934 15590 34905347
Inappropriate schedule of product administration 33.79 16.32 11 35983 62285 34858652
Cardiac arrest 33.26 16.32 30 35964 96129 34824808
Tumour haemorrhage 32.78 16.32 26 35968 2936 34918001
Product administered to patient of inappropriate age 32.43 16.32 27 35967 3264 34917673
Reactive perforating collagenosis 31.13 16.32 6 35988 6 34920931
Intentional product misuse 30.79 16.32 5 35989 45606 34875331
Pyrexia 30.70 16.32 497 35497 332516 34588421
Intentional product use issue 30.00 16.32 12 35982 59804 34861133
Keratoacanthoma 29.24 16.32 14 35980 636 34920301
Bradycardia 29.24 16.32 21 35973 75397 34845540
Therapeutic product effect incomplete 29.09 16.32 8 35986 50533 34870404
Coronary artery disease 29.04 16.32 7 35987 48298 34872639
Metastasis 28.95 16.32 28 35966 4116 34916821
Anxiety 28.81 16.32 36 35958 99392 34821545
Cancer pain 28.60 16.32 23 35971 2649 34918288
Hyperammonaemia 28.53 16.32 34 35960 6333 34914604
Hospitalisation 28.37 16.32 125 35869 56777 34864160
Epistaxis 28.32 16.32 127 35867 58124 34862813
Bone marrow failure 28.30 16.32 80 35914 29173 34891764
Erythema 28.23 16.32 172 35822 88608 34832329
Death 28.22 16.32 570 35424 397479 34523458
Haematemesis 28.01 16.32 77 35917 27634 34893303
Prostate cancer 27.55 16.32 4 35990 39645 34881292
Febrile neutropenia 27.28 16.32 63 35931 136786 34784151
Alanine aminotransferase increased 27.25 16.32 159 35835 80656 34840281
Malaise 26.88 16.32 301 35693 185524 34735413
Hyperamylasaemia 26.62 16.32 13 35981 617 34920320
Agitation 26.45 16.32 13 35981 57386 34863551
Depression 26.25 16.32 37 35957 97061 34823876
Incorrect dose administered 26.13 16.32 5 35989 40510 34880427
Suicidal ideation 26.01 16.32 5 35989 40383 34880554
Septal panniculitis 25.73 16.32 7 35987 57 34920880
Haemobilia 25.44 16.32 11 35983 393 34920544
Lactic acidosis 25.38 16.32 3 35991 34769 34886168
Therapeutic product effect decreased 25.35 16.32 3 35991 34740 34886197
Metastases to liver 24.99 16.32 48 35946 13615 34907322
Sinusitis 24.88 16.32 6 35988 41396 34879541
Genital rash 24.64 16.32 12 35982 566 34920371
Varicose vein ruptured 24.44 16.32 7 35987 70 34920867
Glossodynia 24.03 16.32 24 35970 3669 34917268
Plantar erythema 24.01 16.32 7 35987 75 34920862
Product dose omission issue 23.94 16.32 55 35939 119656 34801281
Varices oesophageal 23.69 16.32 24 35970 3731 34917206
Proteinuria 23.17 16.32 56 35938 18586 34902351
Wheezing 23.00 16.32 7 35987 41395 34879542
Gastric antral vascular ectasia 22.96 16.32 10 35984 364 34920573
Gingival bleeding 22.92 16.32 32 35962 6968 34913969
Chronic obstructive pulmonary disease 22.65 16.32 11 35983 48907 34872030
Asthma 22.32 16.32 8 35986 42648 34878289
Tachycardia 22.23 16.32 33 35961 84739 34836198
General physical health deterioration 21.93 16.32 215 35779 128054 34792883
Hepatic cancer metastatic 21.78 16.32 12 35982 732 34920205
Hyperhidrosis 21.31 16.32 28 35966 75664 34845273
Neuropathy peripheral 21.27 16.32 33 35961 83230 34837707
Hypersensitivity 21.14 16.32 19 35975 61016 34859921
Faeces discoloured 21.02 16.32 47 35947 14831 34906106
Melaena 20.99 16.32 82 35912 35298 34885639
Oxygen saturation decreased 20.84 16.32 15 35979 53803 34867134
Hepatic infarction 20.78 16.32 8 35986 211 34920726
Skin ulcer 20.75 16.32 60 35934 22156 34898781
Nasopharyngitis 20.62 16.32 25 35969 69943 34850994
Rhabdomyolysis 20.46 16.32 24 35970 68139 34852798
Hepatic cirrhosis 20.45 16.32 51 35943 17263 34903674
Influenza 20.36 16.32 13 35981 49653 34871284
Joint swelling 20.32 16.32 19 35975 59871 34861066
Abdominal distension 20.30 16.32 116 35878 58376 34862561
Lower respiratory tract infection 20.20 16.32 4 35990 31633 34889304
Hepatic artery thrombosis 19.81 16.32 8 35986 240 34920697
Metastases to heart 19.63 16.32 7 35987 148 34920789
Chronic kidney disease 19.49 16.32 9 35985 41201 34879736
Stress 19.04 16.32 4 35990 30343 34890594
Glossitis 18.59 16.32 13 35981 1212 34919725
Wrong technique in product usage process 18.40 16.32 7 35987 35979 34884958
Aortic dissection 18.03 16.32 18 35976 2750 34918187
Tumour necrosis 18.00 16.32 13 35981 1275 34919662
Oropharyngeal blistering 17.92 16.32 7 35987 192 34920745
Gastrointestinal perforation 17.92 16.32 21 35973 3842 34917095
Encephalopathy 17.91 16.32 78 35916 35241 34885696
Hypoalbuminaemia 17.81 16.32 39 35955 12135 34908802
Blood lactate dehydrogenase increased 17.67 16.32 58 35936 22932 34898005
Graft versus host disease in skin 17.65 16.32 21 35973 3904 34917033
Thyroid atrophy 17.64 16.32 3 35991 0 34920937
Metastases to gallbladder 17.64 16.32 3 35991 0 34920937
Drug reaction with eosinophilia and systemic symptoms 17.60 16.32 6 35988 33006 34887931
Thyroid cancer metastatic 17.28 16.32 5 35989 52 34920885
Feeding disorder 17.18 16.32 28 35966 6982 34913955
Food refusal 17.03 16.32 7 35987 220 34920717
Tumour embolism 16.79 16.32 5 35989 58 34920879
Syncope 16.72 16.32 44 35950 91407 34829530
Urticaria 16.63 16.32 24 35970 62353 34858584
Albumin urine present 16.46 16.32 8 35986 376 34920561
Electrocardiogram QT prolonged 16.40 16.32 11 35983 40941 34879996

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Palmar-plantar erythrodysaesthesia syndrome 5197.11 16.84 1531 45283 31603 79665971
Hepatic cancer 997.89 16.84 332 46482 10197 79687377
Hepatic function abnormal 898.53 16.84 550 46264 72557 79625017
Hepatic encephalopathy 774.54 16.84 346 46468 23820 79673754
Diarrhoea 721.46 16.84 1586 45228 878903 78818671
Decreased appetite 619.38 16.84 876 45938 341542 79356032
Ascites 574.53 16.84 422 46392 75140 79622434
Metastases to lung 506.12 16.84 236 46578 17927 79679647
Hypertension 477.05 16.84 762 46052 330230 79367344
Hepatic failure 420.91 16.84 322 46492 60890 79636684
Alpha 1 foetoprotein increased 366.98 16.84 87 46727 721 79696853
Rash 254.95 16.84 831 45983 577527 79120047
Amylase increased 243.88 16.84 123 46691 11086 79686488
Hepatocellular carcinoma 226.07 16.84 109 46705 8912 79688662
Dysphonia 221.04 16.84 216 46598 56656 79640918
Hyperkeratosis 207.01 16.84 98 46716 7692 79689882
Blister 202.34 16.84 297 46517 119179 79578395
Skin exfoliation 198.84 16.84 201 46613 54899 79642675
Lipase increased 184.53 16.84 117 46697 16349 79681225
Blood bilirubin increased 180.01 16.84 208 46606 66024 79631550
Drug ineffective 176.00 16.84 227 46587 1080686 78616888
Ammonia increased 175.58 16.84 87 46727 7548 79690026
Jaundice 168.08 16.84 181 46633 53168 79644406
Liver carcinoma ruptured 164.72 16.84 35 46779 164 79697410
Alopecia 155.78 16.84 388 46426 230967 79466607
Dry skin 143.49 16.84 188 46626 67807 79629767
Skin toxicity 140.34 16.84 77 46737 8237 79689337
Platelet count decreased 135.80 16.84 331 46483 194333 79503241
Oesophageal varices haemorrhage 133.52 16.84 60 46754 4176 79693398
Drug hypersensitivity 126.36 16.84 14 46800 298902 79398672
Off label use 123.29 16.84 931 45883 906284 78791290
Completed suicide 122.67 16.84 5 46809 245762 79451812
Stomatitis 117.00 16.84 263 46551 146494 79551080
Renal cell carcinoma 114.01 16.84 62 46752 6516 79691058
Liver disorder 113.91 16.84 174 46640 72243 79625331
Death 109.91 16.84 636 46178 565878 79131696
Rheumatoid arthritis 104.85 16.84 4 46810 208466 79489108
Erythema multiforme 104.30 16.84 85 46729 17566 79680008
Hypophosphataemia 101.39 16.84 88 46726 19825 79677749
Portal vein thrombosis 101.21 16.84 55 46759 5772 79691802
Metastases to bone 100.94 16.84 96 46718 24331 79673243
Pain of skin 100.61 16.84 77 46737 14536 79683038
Toxicity to various agents 100.02 16.84 62 46752 421478 79276096
Condition aggravated 98.04 16.84 90 46724 501034 79196540
Weight decreased 97.66 16.84 440 46374 354758 79342816
Acute myeloid leukaemia recurrent 97.43 16.84 45 46769 3338 79694236
Asthenia 95.65 16.84 569 46245 511120 79186454
Tumour rupture 91.99 16.84 26 46788 453 79697121
Weight increased 91.20 16.84 25 46789 277361 79420213
Overdose 87.88 16.84 5 46809 184201 79513373
Metastases to lymph nodes 85.56 16.84 61 46753 10336 79687238
Fatigue 84.47 16.84 874 45940 928853 78768721
Blood pressure increased 83.15 16.84 293 46521 211067 79486507
Joint swelling 82.66 16.84 33 46781 288613 79408961
Protein induced by vitamin K absence or antagonist II increased 79.99 16.84 14 46800 15 79697559
Therapeutic product effect decreased 79.57 16.84 4 46810 163859 79533715
Sinusitis 78.09 16.84 11 46803 195490 79502084
Malignant neoplasm progression 78.03 16.84 215 46599 135775 79561799
Metastases to adrenals 76.62 16.84 29 46785 1301 79696273
Abdominal pain 74.49 16.84 436 46378 389133 79308441
Aspartate aminotransferase increased 74.46 16.84 214 46600 138427 79559147
Pancreatic enzymes increased 72.31 16.84 28 46786 1337 79696237
Nasopharyngitis 71.10 16.84 30 46784 253851 79443723
Tumour thrombosis 70.65 16.84 17 46797 151 79697423
Fall 70.43 16.84 111 46703 487518 79210056
Hypersensitivity 70.28 16.84 33 46781 262206 79435368
COVID-19 70.23 16.84 6 46808 157668 79539906
Hospitalisation 68.58 16.84 163 46651 94073 79603501
Pyrexia 64.79 16.84 645 46169 678064 79019510
Bone marrow failure 64.29 16.84 111 46703 50996 79646578
Drug interaction 63.33 16.84 91 46723 415092 79282482
Metastases to spine 62.02 16.84 36 46778 4288 79693286
Lower respiratory tract infection 60.14 16.84 4 46810 129216 79568358
Hepatorenal syndrome 59.95 16.84 35 46779 4214 79693360
Arthralgia 59.72 16.84 157 46657 571646 79125928
Cerebral infarction 58.50 16.84 100 46714 45576 79651998
Hypotension 58.25 16.84 106 46708 440211 79257363
Liver abscess 57.99 16.84 39 46775 6015 79691559
Metastases to central nervous system 57.69 16.84 59 46755 16316 79681258
Coma hepatic 56.02 16.84 22 46792 1091 79696483
Pain in extremity 56.00 16.84 386 46428 364152 79333422
Hyperammonaemia 54.41 16.84 48 46766 11045 79686529
Tumour haemorrhage 52.90 16.84 32 46782 4112 79693462
Inappropriate schedule of product administration 52.24 16.84 8 46806 133620 79563954
Gait inability 50.76 16.84 109 46705 58808 79638766
Skin fissures 49.54 16.84 49 46765 13024 79684550
Product administered to patient of inappropriate age 48.99 16.84 34 46780 5519 79692055
Asthma 48.65 16.84 10 46804 135085 79562489
Hepatic lesion 48.63 16.84 37 46777 6922 79690652
Therapeutic product effect incomplete 47.98 16.84 12 46802 141633 79555941
Erythema 47.28 16.84 257 46557 223033 79474541
Food refusal 46.49 16.84 16 46798 544 79697030
Treatment failure 44.82 16.84 22 46792 170464 79527110
Tumour necrosis 44.48 16.84 22 46792 1900 79695674
Nephrotic syndrome 44.43 16.84 43 46771 11131 79686443
Intentional product use issue 44.15 16.84 17 46797 152095 79545479
Metastases to peritoneum 43.89 16.84 29 46785 4343 79693231
Anxiety 43.53 16.84 49 46765 248463 79449111
Swelling 43.39 16.84 38 46776 216673 79480901
Metastatic renal cell carcinoma 43.05 16.84 23 46791 2332 79695242
Musculoskeletal stiffness 42.47 16.84 25 46789 174983 79522591
Plantar erythema 42.27 16.84 13 46801 307 79697267
Varices oesophageal 42.19 16.84 32 46782 5959 79691615
Cancer pain 41.38 16.84 30 46784 5215 79692359
Product use in unapproved indication 41.34 16.84 270 46544 250089 79447485
Pericarditis 41.29 16.84 6 46808 104230 79593344
Acute kidney injury 40.68 16.84 162 46652 519242 79178332
Pleural effusion 40.60 16.84 181 46633 145081 79552493
Hepatic rupture 40.49 16.84 10 46804 100 79697474
Metastasis 40.37 16.84 33 46781 6847 79690727
Metastases to liver 40.29 16.84 65 46749 28249 79669325
Proteinuria 40.10 16.84 70 46744 32432 79665142
Epistaxis 39.91 16.84 150 46664 111365 79586209
Pain 39.39 16.84 247 46567 703555 78994019
Wheezing 37.41 16.84 11 46803 116653 79580921
Gastric ulcer 36.71 16.84 69 46745 33836 79663738
Blood lactate dehydrogenase increased 36.69 16.84 75 46739 39095 79658479
Arthritis 36.53 16.84 11 46803 114869 79582705
Discomfort 36.52 16.84 14 46800 125603 79571971
Alanine aminotransferase increased 35.67 16.84 189 46625 162381 79535193
Bronchitis 35.66 16.84 16 46798 130628 79566946
Wound 35.39 16.84 12 46802 116167 79581407
Reactive perforating collagenosis 34.49 16.84 6 46808 6 79697568
Gingival bleeding 34.30 16.84 45 46769 16231 79681343
Abdominal pain upper 33.72 16.84 236 46578 223583 79473991
Headache 32.78 16.84 237 46577 653535 79044039
Abdominal distension 32.61 16.84 148 46666 119502 79578072
Pneumonia adenoviral 32.55 16.84 12 46802 500 79697074
Intentional product misuse 32.34 16.84 8 46806 95157 79602417
Haematemesis 32.33 16.84 85 46729 52179 79645395
Upper respiratory tract infection 32.30 16.84 7 46807 91161 79606413
Oxygen saturation decreased 31.92 16.84 18 46796 129029 79568545
Dehydration 31.89 16.84 252 46562 247935 79449639
Injury 31.79 16.84 4 46810 77492 79620082
Melaena 31.71 16.84 93 46721 60797 79636777
Gastric antral vascular ectasia 31.57 16.84 14 46800 944 79696630
Catabolic state 31.38 16.84 8 46806 92 79697482
Oropharyngeal blistering 30.89 16.84 13 46801 771 79696803
Cardiac arrest 30.05 16.84 34 46780 172062 79525512
Oral pain 29.92 16.84 61 46753 31737 79665837
Dysphagia 29.58 16.84 146 46668 121990 79575584
Palmoplantar keratoderma 28.74 16.84 21 46793 3695 79693879
Pneumonia 28.62 16.84 249 46565 659997 79037577
Migraine 28.51 16.84 8 46806 87485 79610089
Stress 28.44 16.84 6 46808 79606 79617968
Osteoarthritis 28.42 16.84 8 46806 87301 79610273
Influenza 28.08 16.84 21 46793 129585 79567989
Bradycardia 28.06 16.84 23 46791 135534 79562040
Depression 27.90 16.84 53 46761 216737 79480837
Lymphadenopathy mediastinal 27.73 16.84 22 46792 4374 79693200
Keratoacanthoma 27.31 16.84 13 46801 1032 79696542
Medication error 27.07 16.84 4 46810 68638 79628936
Gastrointestinal perforation 27.04 16.84 25 46789 6112 79691462
Nasal congestion 26.88 16.84 6 46808 76546 79621028
Hypocalcaemia 26.71 16.84 77 46737 49847 79647727
Hypoalbuminaemia 26.44 16.84 46 46768 21251 79676323
Glossitis 26.43 16.84 20 46794 3710 79693864
General physical health deterioration 26.33 16.84 262 46552 274976 79422598
Hyperamylasaemia 26.16 16.84 13 46801 1134 79696440
Duodenal ulcer perforation 25.79 16.84 4 46810 66207 79631367
Adenoviral hepatitis 25.67 16.84 12 46802 915 79696659
Skin ulcer 25.65 16.84 80 46734 54070 79643504
Hyperbilirubinaemia 25.43 16.84 49 46765 24469 79673105
Faeces discoloured 25.21 16.84 54 46760 29073 79668501
Urinary tract infection 25.20 16.84 80 46734 274432 79423142
Haemobilia 25.05 16.84 10 46804 518 79697056
Incorrect dose administered 24.98 16.84 7 46807 76623 79620951
Urticaria 24.96 16.84 44 46770 185157 79512417
Anaphylactic reaction 24.90 16.84 9 46805 83734 79613840
Cholangitis 24.90 16.84 34 46780 12742 79684832
Suicidal ideation 24.83 16.84 7 46807 76333 79621241
Fluid intake reduced 24.63 16.84 24 46790 6264 79691310
Blood albumin decreased 24.60 16.84 48 46766 24195 79673379
Aortic dissection 24.44 16.84 20 46794 4155 79693419
Septal panniculitis 24.30 16.84 7 46807 131 79697443
Neutropenia 24.26 16.84 87 46727 287623 79409951
Mucosal inflammation 24.06 16.84 98 46716 75482 79622092
Tumour marker increased 24.04 16.84 20 46794 4252 79693322
Renal cell carcinoma stage IV 23.61 16.84 6 46808 68 79697506
Hepatic cancer metastatic 23.30 16.84 11 46803 857 79696717
Blood cholesterol increased 23.24 16.84 10 46804 83710 79613864
Haemoptysis 23.16 16.84 79 46735 55920 79641654
Gastrointestinal toxicity 22.91 16.84 26 46788 8083 79689491
Metastases to abdominal cavity 22.84 16.84 10 46804 654 79696920
Metastases to heart 22.84 16.84 8 46806 287 79697287
Hyperhidrosis 22.27 16.84 34 46780 151458 79546116
Thyroid cancer metastatic 22.12 16.84 7 46807 182 79697392
Agitation 21.80 16.84 16 46798 99699 79597875
Hiccups 21.55 16.84 28 46786 10003 79687571
Cataract 21.54 16.84 5 46809 62115 79635459
Product dose omission issue 21.43 16.84 74 46740 247463 79450111
Feeding disorder 21.35 16.84 36 46778 16218 79681356
Rhinorrhoea 21.26 16.84 9 46805 76065 79621509
Gastrointestinal haemorrhage 21.21 16.84 154 46660 147565 79550009
Chronic obstructive pulmonary disease 21.00 16.84 12 46802 85407 79612167
Hepatic pain 20.73 16.84 18 46796 4054 79693520
Dizziness 20.43 16.84 204 46610 526237 79171337
Disease progression 20.36 16.84 181 46633 184181 79513393
Tumour pain 20.10 16.84 14 46800 2285 79695289
Eating disorder 19.82 16.84 40 46774 20657 79676917
Varicose vein ruptured 19.78 16.84 6 46808 135 79697439
Sleep disorder 19.72 16.84 13 46801 85664 79611910
Somnolence 19.65 16.84 73 46741 238908 79458666
Encephalopathy 19.59 16.84 85 46729 67312 79630262
Osteoporosis 19.49 16.84 4 46810 54108 79643466
Blood sodium decreased 19.47 16.84 53 46761 33202 79664372
Alpha 1 foetoprotein abnormal 19.19 16.84 5 46809 63 79697511
Skin lesion 19.06 16.84 61 46753 41783 79655791
Type 2 diabetes mellitus 19.03 16.84 5 46809 57117 79640457
Wrong technique in product usage process 18.71 16.84 10 46804 73865 79623709
Genital rash 18.68 16.84 10 46804 1018 79696556
Cognitive disorder 18.40 16.84 9 46805 69917 79627657
Tumour lysis syndrome 18.04 16.84 42 46772 23897 79673677
Coronary artery disease 17.89 16.84 8 46806 65466 79632108
Aggression 17.87 16.84 4 46810 50954 79646620
Illness 17.69 16.84 3 46811 46508 79651066
Gamma-glutamyltransferase increased 17.48 16.84 71 46743 54609 79642965
Gastrointestinal disorder 17.42 16.84 28 46786 122177 79575397
Metastases to pleura 17.30 16.84 11 46803 1543 79696031
Tongue blistering 17.27 16.84 11 46803 1548 79696026
Bleeding varicose vein 17.10 16.84 8 46806 611 79696963
Therapeutic response decreased 17.00 16.84 9 46805 66844 79630730

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01EX02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
PROTEIN KINASE INHIBITORS
Other protein kinase inhibitors
FDA MoA N0000175076 Protein Kinase Inhibitors
MeSH PA D000970 Antineoplastic Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D047428 Protein Kinase Inhibitors
FDA EPC N0000175605 Kinase Inhibitor
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:38637 tyrosine kinase inhibitors
CHEBI has role CHEBI:48422 angiogenesis antagonist
CHEBI has role CHEBI:50925 serine/threonine protein kinase inhibitor
CHEBI has role CHEBI:149553 anticoronaviral drug
CHEBI has role CHEBI:173085 ferroptosis inducers

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Liver cell carcinoma indication 109841003 DOID:684
Carcinoma of thyroid indication 448216007
Renal cell carcinoma indication 702391001 DOID:4450
Hypophosphatemia contraindication 4996001
Acute hemorrhage contraindication 8573003
Myocardial infarction contraindication 22298006 DOID:5844
Depressive disorder contraindication 35489007
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal perforation contraindication 51875005
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Pancreatitis contraindication 75694006 DOID:4989
Angina pectoris contraindication 194828000
Impaired wound healing contraindication 271618001
Anemia contraindication 271737000 DOID:2355
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Neutropenic disorder contraindication 303011007 DOID:1227
Surgical procedure contraindication 387713003
Acute coronary syndrome contraindication 394659003
Breastfeeding (mother) contraindication 413712001
Disorder of coronary artery contraindication 414024009
Myocardial ischemia contraindication 414795007 DOID:3393




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.84 acidic
pKa2 11.97 acidic
pKa3 12.61 acidic
pKa4 2.76 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 8618141 Feb. 11, 2023 TREATMENT OF ADVANCED RENAL CELL CARCINOMA
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 8877933 Dec. 24, 2027 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA, ADVANCED RENAL CELL CARCINOMA, OR DIFFERENTIATED THYROID CARCINOMA.
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 9737488 Sept. 10, 2028 TREATMENT OF ADVANCED RENAL CELL CARCINOMA
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 9737488 Sept. 10, 2028 TREATMENT OF LOCALLY RECURRENT OR METASTATIC, PROGRESSIVE, DIFFERENTIATED THYROID CARCINOMA REFRACTORY TO RADIOACTIVE IODINE TREATMENT
EQ 200MG BASE NEXAVAR BAYER HLTHCARE N021923 Dec. 20, 2005 RX TABLET ORAL 9737488 Sept. 10, 2028 TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Mast/stem cell growth factor receptor Kit Kinase INHIBITOR Kd 7.80 CHEMBL CHEMBL
RAF proto-oncogene serine/threonine-protein kinase Kinase INHIBITOR Ki 8.22 CHEMBL CHEMBL
Serine/threonine-protein kinase B-raf Kinase INHIBITOR Ki 7.66 CHEMBL CHEMBL
Receptor-type tyrosine-protein kinase FLT3 Kinase INHIBITOR Kd 8.35 CHEMBL CHEMBL
Proto-oncogene tyrosine-protein kinase receptor Ret Kinase INHIBITOR Kd 8.13 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 1 Kinase INHIBITOR Kd 7.51 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 2 Kinase INHIBITOR Ki 10.68 CHEMBL CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR Kd 7.80 CHEMBL CHEMBL
Platelet-derived growth factor receptor beta Kinase INHIBITOR Kd 7.43 CHEMBL CHEMBL
5-hydroxytryptamine receptor 5A GPCR Ki 5.48 CHEMBL
Tyrosine-protein kinase ABL1 Kinase Kd 6.89 CHEMBL
Epidermal growth factor receptor Kinase IC50 8.53 CHEMBL
Carbonic anhydrase 7 Enzyme Ki 5.09 CHEMBL
Proto-oncogene tyrosine-protein kinase Src Kinase IC50 6.41 CHEMBL
Tyrosine-protein kinase Lck Kinase Kd 5.57 CHEMBL
Tyrosine-protein kinase Fyn Kinase Kd 5.08 CHEMBL
Ephrin type-A receptor 2 Kinase Kd 5.70 CHEMBL
Macrophage colony-stimulating factor 1 receptor Kinase Kd 7.55 CHEMBL
Platelet-derived growth factor receptor alpha Kinase Kd 7.21 CHEMBL
Receptor tyrosine-protein kinase erbB-2 Kinase IC50 6.88 CHEMBL
Cyclin-dependent kinase 2 Kinase Kd 5.06 CHEMBL
Insulin receptor Kinase AGONIST IC50 5.28 CHEMBL
Fibroblast growth factor receptor 3 Kinase Kd 5.38 CHEMBL
Tyrosine-protein kinase HCK Kinase Kd 5.07 CHEMBL
High affinity nerve growth factor receptor Kinase Kd 5.44 CHEMBL
Myosin light chain kinase 2, skeletal/cardiac muscle Kinase Kd 5.89 CHEMBL
Tyrosine-protein kinase CSK Kinase Kd 5.54 CHEMBL
Angiopoietin-1 receptor Kinase Kd 5.68 CHEMBL
Ephrin type-A receptor 8 Kinase Kd 6.02 CHEMBL
Hepatocyte growth factor receptor Kinase IC50 5.24 CHEMBL
Tyrosine-protein kinase Lyn Kinase Kd 5.52 CHEMBL
LIM domain kinase 1 Kinase Kd 5.80 CHEMBL
Fibroblast growth factor receptor 1 Kinase Kd 5.60 CHEMBL
Cyclin-dependent-like kinase 5 Kinase Kd 5.21 CHEMBL
Serine/threonine-protein kinase 10 Kinase Kd 6.85 CHEMBL
Serine/threonine-protein kinase PLK4 Kinase Kd 5.47 CHEMBL
Aurora kinase C Kinase Kd 6.68 CHEMBL
Dual specificity protein kinase TTK Kinase Kd 5.46 CHEMBL
Abelson tyrosine-protein kinase 2 Kinase Kd 5.89 CHEMBL
Mitogen-activated protein kinase 11 Kinase Kd 6.70 CHEMBL
Ephrin type-A receptor 5 Kinase Kd 6.44 CHEMBL
Ephrin type-A receptor 4 Kinase Kd 5.89 CHEMBL
Fibroblast growth factor receptor 2 Kinase Kd 5.57 CHEMBL
Mitogen-activated protein kinase 3 Kinase IC50 7.74 CHEMBL
Ephrin type-A receptor 6 Kinase Kd 6.62 CHEMBL
TRAF2 and NCK-interacting protein kinase Kinase Kd 5.10 CHEMBL
Mitogen-activated protein kinase 12 Kinase Kd 5.12 CHEMBL
Tyrosine-protein kinase Fgr Kinase Kd 5.11 CHEMBL
Aurora kinase A Kinase IC50 5.42 CHEMBL
Serine/threonine-protein kinase 36 Kinase Kd 5.42 CHEMBL
Ephrin type-A receptor 3 Kinase Kd 5.72 CHEMBL
Mitogen-activated protein kinase 14 Kinase Kd 6.59 CHEMBL
Tyrosine-protein kinase FRK Kinase Kd 6.36 CHEMBL
Dual specificity protein kinase CLK1 Kinase Kd 5.12 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 5 Kinase Kd 5.80 CHEMBL
Glycogen synthase kinase-3 beta Kinase IC50 5.08 CHEMBL
Receptor-interacting serine/threonine-protein kinase 2 Kinase Kd 5.89 CHEMBL
Ephrin type-B receptor 1 Kinase Kd 5.77 CHEMBL
Ephrin type-A receptor 7 Kinase Kd 6.17 CHEMBL
STE20-like serine/threonine-protein kinase Kinase Kd 6 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 2 Kinase Kd 6.89 CHEMBL
Mitogen-activated protein kinase 9 Kinase Kd 5.44 CHEMBL
Epithelial discoidin domain-containing receptor 1 Kinase Kd 8.82 CHEMBL
Ephrin type-B receptor 4 Kinase Kd 5.74 CHEMBL
Cyclin-dependent kinase 15 Kinase Kd 5.54 CHEMBL
Bifunctional epoxide hydrolase 2 Enzyme IC50 7.92 CHEMBL
TGF-beta receptor type-2 Kinase Kd 5.16 CHEMBL
Mitogen-activated protein kinase 1 Kinase IC50 6.96 CHEMBL
Cyclin-dependent kinase 6 Kinase IC50 6.89 CHEMBL
Tyrosine-protein kinase receptor UFO Kinase Kd 5.35 CHEMBL
BDNF/NT-3 growth factors receptor Kinase Kd 5.68 CHEMBL
Ephrin type-B receptor 2 Kinase Kd 5.72 CHEMBL
Cyclin-dependent kinase 7 Kinase Kd 6.85 CHEMBL
Ribosomal protein S6 kinase alpha-6 Kinase Kd 5.12 CHEMBL
Non-receptor tyrosine-protein kinase TNK1 Kinase Kd 5.64 CHEMBL
Mitogen-activated protein kinase 13 Kinase Kd 5.18 CHEMBL
Cyclin-dependent kinase 17 Kinase Kd 5.80 CHEMBL
Cyclin-dependent kinase 14 Kinase Kd 5.54 CHEMBL
Mitogen-activated protein kinase kinase kinase MLT Kinase Kd 8.20 CHEMBL
Tyrosine-protein kinase receptor Tie-1 Kinase Kd 7.17 CHEMBL
NT-3 growth factor receptor Kinase Kd 6.22 CHEMBL
LIM domain kinase 2 Kinase Kd 5.02 CHEMBL
MAP kinase-interacting serine/threonine-protein kinase 1 Kinase Kd 6.64 CHEMBL
Serine/threonine-protein kinase NLK Kinase Kd 6.19 CHEMBL
Serine/threonine-protein kinase 33 Kinase Kd 5.62 CHEMBL
Serine/threonine-protein kinase TNNI3K Kinase Kd 6.55 CHEMBL
Discoidin domain-containing receptor 2 Kinase Kd 8.18 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 1 Kinase Kd 5.32 CHEMBL
Aurora kinase B Kinase Kd 6.36 CHEMBL
Mitogen-activated protein kinase kinase kinase kinase 4 Kinase Kd 5.32 CHEMBL
Tyrosine-protein kinase Mer Kinase Kd 5.44 CHEMBL
Cyclin-dependent kinase 19 Kinase Kd 6.60 CHEMBL
Cyclin-dependent kinase 8 Kinase Kd 6.51 CHEMBL
Muscle, skeletal receptor tyrosine-protein kinase Kinase Kd 6.89 CHEMBL
Citron Rho-interacting kinase Kinase Kd 5.21 CHEMBL
Myosin-IIIb Kinase Kd 5.15 CHEMBL
Cyclin-dependent kinase 3 Kinase Kd 5.42 CHEMBL
Tyrosine-protein kinase Srms Kinase Kd 5.01 CHEMBL
Ephrin type-A receptor 1 Kinase Kd 5.51 CHEMBL
Receptor-interacting serine/threonine-protein kinase 1 Kinase IC50 5.82 CHEMBL
Casein kinase I isoform alpha Kinase IC50 6.60 CHEMBL
Cyclin-dependent kinase-like 2 Kinase Kd 6.89 CHEMBL
Cyclin-dependent kinase-like 3 Kinase Kd 6.31 CHEMBL
Ephrin type-B receptor 6 Kinase Kd 6.62 CHEMBL
Homeodomain-interacting protein kinase 2 Kinase Kd 5.77 CHEMBL
Homeodomain-interacting protein kinase 3 Kinase Kd 6.41 CHEMBL
Homeodomain-interacting protein kinase 4 Kinase Kd 8.57 CHEMBL
Mitogen-activated protein kinase kinase kinase 7 Kinase Kd 6.16 CHEMBL
Serine/threonine-protein kinase TAO1 Kinase Kd 6.27 CHEMBL
Serine/threonine-protein kinase TAO3 Kinase Kd 5.57 CHEMBL
Mitogen-activated protein kinase kinase kinase 19 Kinase Kd 7 CHEMBL
Homeodomain-interacting protein kinase 1 Kinase Kd 5.96 CHEMBL
Mitogen-activated protein kinase kinase kinase 1 Kinase Kd 5.42 CHEMBL
Serine/threonine-protein kinase TAO2 Kinase Kd 6.27 CHEMBL
Dual specificity mitogen-activated protein kinase kinase 5 Kinase Kd 6.72 CHEMBL
Myosin light chain kinase 3 Kinase Kd 5.02 CHEMBL
Serine/threonine-protein kinase A-Raf Kinase IC50 8.15 CHEMBL
Receptor-interacting serine/threonine-protein kinase 3 Kinase IC50 4.84 CHEMBL
Mitogen-activated protein kinase 15 Kinase Kd 7.34 CHEMBL
Tyrosine-protein kinase JAK3 Kinase Kd 5.14 CHEMBL
5-hydroxytryptamine receptor 1A GPCR Ki 5.93 CHEMBL
5-hydroxytryptamine receptor 2A GPCR Ki 5.71 CHEMBL
5-hydroxytryptamine receptor 2B GPCR Ki 7.25 CHEMBL
5-hydroxytryptamine receptor 2C GPCR Ki 6.38 CHEMBL
5-hydroxytryptamine receptor 6 GPCR Ki 5.21 CHEMBL
5-hydroxytryptamine receptor 7 GPCR Ki 5.15 CHEMBL
ATP-binding cassette sub-family G member 2 Transporter IC50 5.51 CHEMBL
Tyrosine-protein kinase ABL1 Kinase IC50 6.65 CHEMBL
Calcium-dependent protein kinase 1 Kinase Kd 6.66 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 7.82 CHEMBL
Vascular endothelial growth factor receptor 2 Kinase IC50 5.59 CHEMBL
Purine nucleoside phosphorylase Enzyme IC50 7.90 CHEMBL
Vascular endothelial growth factor receptor 3 Kinase INHIBITOR IC50 7.70 IUPHAR
Platelet-derived growth factor receptor beta Kinase INHIBITOR IC50 7.24 IUPHAR
Serine/threonine-protein kinase B-raf Kinase IC50 6.89 CHEMBL

External reference:

IDSource
4025077 VUID
N0000175349 NUI
D06272 KEGG_DRUG
475207-59-1 SECONDARY_CAS_RN
4025077 VANDF
C1516119 UMLSCUI
CHEBI:50924 CHEBI
BAX PDB_CHEM_ID
CHEMBL1336 ChEMBL_ID
CHEMBL1200485 ChEMBL_ID
D000077157 MESH_DESCRIPTOR_UI
DB00398 DRUGBANK_ID
5711 IUPHAR_LIGAND_ID
8234 INN_ID
9ZOQ3TZI87 UNII
216239 PUBCHEM_CID
495881 RXNORM
20792 MMSL
348700 MMSL
73580 MMSL
d05691 MMSL
011160 NDDF
011161 NDDF
420681006 SNOMEDCT_US
422042001 SNOMEDCT_US
432886002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Sorafenib Tosylate HUMAN PRESCRIPTION DRUG LABEL 1 0378-1201 TABLET, FILM COATED 200 mg ORAL ANDA 29 sections
Sorafenib HUMAN PRESCRIPTION DRUG LABEL 1 0480-5425 TABLET, FILM COATED 200 mg ORAL ANDA 27 sections
Sorafenib HUMAN PRESCRIPTION DRUG LABEL 1 13668-682 TABLET, FILM COATED 200 mg ORAL ANDA 28 sections
sorafenib HUMAN PRESCRIPTION DRUG LABEL 1 24979-715 TABLET, FILM COATED 200 mg ORAL ANDA 18 sections
sorafenib HUMAN PRESCRIPTION DRUG LABEL 1 43598-458 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
sorafenib HUMAN PRESCRIPTION DRUG LABEL 1 43598-458 TABLET, FILM COATED 200 mg ORAL ANDA 26 sections
Nexavar HUMAN PRESCRIPTION DRUG LABEL 1 50419-488 TABLET, FILM COATED 200 mg ORAL NDA 28 sections
Nexavar HUMAN PRESCRIPTION DRUG LABEL 1 50419-488 TABLET, FILM COATED 200 mg ORAL NDA 28 sections
Sorafenib HUMAN PRESCRIPTION DRUG LABEL 1 51407-760 TABLET, FILM COATED 200 mg ORAL ANDA 29 sections
Sorafenib HUMAN PRESCRIPTION DRUG LABEL 1 51990-201 TABLET, FILM COATED 200 mg ORAL ANDA 29 sections